Use of natural molecules as anti-angiogenic inhibitors for vascular endothelial growth factor receptor

被引:14
|
作者
Chatterjee, Subhojyoti [1 ]
Bhattacharjee, Biplab [2 ]
机构
[1] Indian Inst Sci, Mol Biophys Unit, Room 4,Annex Bldg, Bangalore 560012, Karnataka, India
[2] PES Inst Technol, Bangalore, Karnataka, India
关键词
Angiogenesis; VEGF; chemopreventive agent; pharmacokinetics study; Lipinski's rule;
D O I
10.6026/97320630081249
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Angiogenesis refers to the formation of new blood vessels, controlled by certain chemicals, which on stimulation repairs damaged cells or form new ones. Other chemicals, called angiogenesis inhibitors, signal the process to stop, having only mild side effects and are non toxic to most healthy cells. In our study, attempt was made to find potent anti-angiogenic inhibitor (pazopanib was considered as a reference drug) for vascular endothelial growth factor receptor (VEGFR-1/FLT-1), which served as a molecular target, using natural agents targeting biological processes important in cancer. Hundreds of natural molecules were initially screened based on lipinski's rule of five and the satisfying ones were taken for receptor-ligand interaction study using docking tools like HEX and quantum. Around fifteen molecules were taken as lead molecule and their binding pocket on VEGF was analyzed using SwissPDBviewer and Q-site finder. The investigational drug pazopanib was found to be interacting with leucine 32 and glutamine 30 in terms of hydrogen bond with the distance of 1.86 and 2.49 A(0) respectively. Ames test for the molecules was predicted for probability of mutagenicity on molecular systems such as blood, cardiovascular system, gastrointestinal system; kidney, liver and lung were considered for further screening of the molecules. The natural molecules curcumin, epigallocatechin gallate (EGCG), barrigtozenol and finasteride were showing reliable interaction with VEGFR and their pharmacokinetics parameters were comparatively good than the pazopanib. The dietary product curcumin and EGCG can be cancer chemopreventive agents and the natural molecules barringtozenol and finasteride can be effective inhibitors for VEGFR.
引用
收藏
页码:1249 / 1254
页数:6
相关论文
共 50 条
  • [1] Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy
    Veeravagu, Anand
    Hsu, Andrew R.
    Cai, Weibo
    Hou, Lewis C.
    Tse, Victor C. K.
    Chen, Xiaoyuan
    [J]. RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2007, 2 (01) : 59 - 71
  • [2] Vascular endothelial growth factor and anti-angiogenic peptides as therapeutic and investigational molecules
    Zachary, I
    [J]. IDRUGS, 2003, 6 (03) : 224 - 231
  • [3] Vorolanib, sunitinib, and axitinib: A comparative study of vascular endothelial growth factor receptor inhibitors and their anti-angiogenic effects
    Bakri, Sophie J.
    Lynch, Jeff
    Howard-Sparks, Michelle
    Saint-Juste, Stephan
    Saim, Said
    [J]. PLOS ONE, 2024, 19 (06):
  • [4] Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy
    Underiner, TL
    Ruggeri, B
    Gingrich, DE
    [J]. CURRENT MEDICINAL CHEMISTRY, 2004, 11 (06) : 731 - 745
  • [5] Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling
    Christophe F Deroanne
    Karine Bonjean
    Sandrine Servotte
    Laetitia Devy
    Alain Colige
    Nathalie Clausse
    Sylvia Blacher
    Eric Verdin
    Jean-Michel Foidart
    Betty V Nusgens
    Vincent Castronovo
    [J]. Oncogene, 2002, 21 : 427 - 436
  • [6] Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling
    Deroanne, CF
    Bonjean, K
    Servotte, S
    Devy, L
    Colige, A
    Clausse, N
    Blacher, S
    Verdin, E
    Foidart, JM
    Nusgens, BV
    Castronovo, V
    [J]. ONCOGENE, 2002, 21 (03) : 427 - 436
  • [7] Anti-angiogenic Agents: A Review on Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Inhibitors
    Cheng, Kang
    Liu, Chen-Fu
    Rao, Guo-Wu
    [J]. CURRENT MEDICINAL CHEMISTRY, 2021, 28 (13) : 2540 - 2564
  • [8] Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy
    Niu, Gang
    Chen, Xiaoyuan
    [J]. CURRENT DRUG TARGETS, 2010, 11 (08) : 1000 - 1017
  • [9] Piceatannol, a Natural Analog of Resveratrol, Exerts Anti-angiogenic Efficiencies by Blockage of Vascular Endothelial Growth Factor Binding to Its Receptor
    Hu, Wei-Hui
    Dai, Diana Kun
    Zheng, Brody Zhong-Yu
    Duan, Ran
    Dong, Tina Ting-Xia
    Qin, Qi-Wei
    Tsim, Karl Wah-Keung
    [J]. MOLECULES, 2020, 25 (17):
  • [10] Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy
    Pasqualetti, Giuseppe
    Danesi, Romano
    Del Tacca, Mario
    Bocci, Guido
    [J]. PHARMACOGENOMICS, 2007, 8 (01) : 49 - 66